News

Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward
Ligand Pharmaceuticals offers investors exposure to dozens of therapies, reducing risk and increasing upside potential. See ...
Verona Pharma price target raised to $160 from $76 at Piper Sandler
Piper Sandler raised the firm’s price target on Verona Pharma (VRNA) to $160 from $76 and keeps an Overweight rating on the shares. Verona Pharma remains one of Piper’s top 2025 picks, where Street ...
Roth Capital Hikes Verona Pharma’s (VRNA) Price Target to $116 On COPD Market Prospects
Verona Pharma plc (NASDAQ:VRNA) is one of the 10 biotech stocks screaming a buy. On June 17, Roth Capital increased its price ...